All blood glucose values; insulin doses; nutritional support including intravenous dextrose infusions; caloric values for enteral and parenteral nutrition; and use of vasopressors, corticosteroids, and hemodialysis or continuous venovenous hemodialysis were collected from the hospital record.

Results: The IIP was used 115 times in 90 patients (mean age, 62 [+/- 14 years]; 51% male; 35% ethnic minorities; 66.1% with

history of diabetes). The mean admission Acute Physiology and Chronic Health Evaluation II score was 24.4 (+/- 7.5). The median duration of insulin infusion was Selleckchem Ferrostatin-1 59 hours. The mean baseline blood glucose concentration was 306.1 (+/- 89.8) mg/dL, with the blood glucose target achieved after a median of 7 hours. Once the target was reached, the mean IIP blood glucose concentration was 155.9. (+/- 22.9) mg/dL (median, 150 mg/dL). The median insulin infusion rate required to reach and maintain the target range was 3.5 units/h. Hypoglycemia was rare, with 0.3%

of blood glucose values recorded being less than 70 mg/dL and only 0.02% being less than 40 mg/dL. In all cases, hypoglycemia was rapidly corrected using intravenous dextrose with no evident untoward outcomes.

Conclusions: click here The updated Yale IIP provides effective and safe targeted blood glucose control in critically ill patients, in compliance with recent national guidelines. It call be easily implemented by hospitals now using the original Yale IIP. (Endocr Pract. 2012;18:363-370)”
“Recent studies demonstrated that mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was high when vancomycin was used to treat infections with strains that had a high vancomycin minimum inhibitory concentration (MIC). This study compared several characteristics of vancomycin MIC 2 mu g/ml strains

see more isolated from bacteremia with those isolated from infections other than bacteremia. A total of 128 episodes of MRSA bacteremia between 2005 and 2008 were followed-up, and compared with 631 MRSA infections other than bacteremia. The isolation of strains with a 2 mu g/ml MIC accounted for 32.0% of isolates from MRSA bacteremia, whereas strains with a 2 mu g/ml MIC comprised 9.0% of MRSA isolated from other sites (p < 0.001). The incidence of pneumonia as the source of infection was significantly higher in patients with bacteremia from strains with a 2 mu g/ml MIC than in those with a parts per thousand currency sign1 mu g/ml MIC. Prior vancomycin use did not correlate with the isolation of 2 mu g/ml strains. The efficacy of glycopeptides as 1st line therapy in patients infected with 2 mu g/ml strains was significantly lower than that for patients infected with a parts per thousand currency sign1 mu g/ml strains (30.0 vs. 78.8%, p < 0.001) in bacteremia.